Drug Profile
ENU 200
Alternative Names: ENU200Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Catholic University of Murcia; Ennaid Therapeutics
- Developer Ennaid Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action Glycoprotein inhibitors; Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 02 Apr 2020 Ennaid Therapeutics has patent pending for ENU 200
- 02 Apr 2020 Ennaid Therapeutics plans to launch ENU 200 in COVID-2019 infections (PO) by end-2020
- 02 Apr 2020 Ennaid Therapeutics plans an in-home phase III trial in COVID-2019 infections (using the company's iClickCare® secure clinical reporting software service) (PO) after discussion with US FDA and other regulatory agencies